Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of SAR405838 in advanced cancer
NL-OMON44662Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SAR-405838 in cancer, Nonhematologic neoplasms, lymphoma and 1 more, sponsored by Sanofi. Primary endpoints: Maximum tolerated dose, Clinical benefit in MTD cohort and 1 more. Started Jul 2012; status: active, not recruiting.
02
Drugs
SAR-405838
03
Conditions
cancerNonhematologic neoplasmslymphomaLiposarcoma
Beyond the preview
Go deeper on NL-OMON44662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44662.